RIGHI, Luisella

RIGHI, Luisella  

ONCOLOGIA  

Mostra records
Risultati 1 - 20 di 125 (tempo di esecuzione: 0.052 secondi).
Titolo Data di pubblicazione Autore(i) File
34betaE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast. 2001 PAPOTTI M ;SAPINO A ;RIGHI L ;CHIAPPONE S ;BUSSOLATI G
A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer 2005 BUSSOLATI G; MONTEMURRO F; RIGHI L; DONADIO M; AGLIETTA M; SAPINO A
A new prognostic score in patients with malignant pleural mesothelioma. 2010 G. Selvaggi; A. Billè; M. Gisabella; L. Righi; L. Errico; P. Borasio; F. Ardissone.
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 2019 Villanova, Tania; Gesmundo, Iacopo; Audrito, Valentina; Vitale, Nicoletta; Silvagno, Francesca; Musuraca, Chiara; Righi, Luisella; Libener, Roberta; Riganti, Chiara; Bironzo, Paolo; Deaglio, Silvia; Papotti, Mauro; Cai, Renzhi; Sha, Wei; Ghigo, Ezio; Schally, Andrew V; Granata, Riccarda
An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation 2015 Cheung, Mitchell; Kadariya, Yuwaraj; Pei, Jianming; Talarchek, Jacqueline; Facciolo, Francesco; Visca, Paolo; Righi, Luisella; Cozzi, Ilaria; Testa, Joseph R.; Ascoli, Valeria
Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma 2007 MARCI V; VOLANTE M; CAPPIA S; RIGHI L; NOVELLO C; SCAGLIOTTI GV; BRAMBILLA E; PAPOTTI M
Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study 2016 Righi, Luisella; Duregon, Eleonora; Vatrano, Simona; Izzo, Stefania; Giorcelli, Jessica; Rondón-Lagos, Milena; Ascoli, Valeria; Ruffini, Enrico; Ventura, Laura; Volante, Marco; Papotti, Mauro; Scagliotti, Giorgio Vittorio
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 2017 Riganti, Chiara***; Lingua, MARCELLO FRANCESCO; Salaroglio, IRIS CHIARA; Falcomatà, Chiara; Righi, Luisella; Morena, Deborah; Francesca, Picca; Oddo, Daniele; Kopecka, Joanna; Pradotto, Monica; Libener, Roberta; Orecchia, Sara; Bironzo, Paolo; Comunanza, Valentina; Bussolino, Federico; Novello, Silvia; Scagliotti, Giorgio Vittorio; DI NICOLANTONIO, Federica***; Taulli, Riccardo***; ***corresponding authors
Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression 2017 Di Stefano, A; Ricciardolo, Flm; Caramori, G; Adcock, Im; Chung, Kf; Barnes, Pj; Brun, P; Leonardi, A; Andò, F; Vallese, D; Gnemmi, I; Righi, L; Cappello, F; Balbi, B.
Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases 2009 Cassoni P; Daniele L; Maldi E; Righi L; Tavaglione V; Novello S; Volante M; Scagliotti GV; Papotti M.
CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. 2014 Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
CD157 is a novel prognostic marker of malignant pleural mesothelioma involved in the control of tumor aggressiveness 2012 A. Giacomino; S. Morone; R. Parrotta; N. Lo Buono; I. Rapa; L. Righi; M. Volante; E. Ruffini; E. Ortolan; A. Funaro
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma 2016 Betti, M; Aspesi, A; Biasi, A; Casalone, E; Ferrante, D; Ogliara, P; Gironi, Lc; Giorgione, R; Farinelli, P; Grosso, F; Libener, R; Rosato, S; Turchetti, D; Maffè, A; Casadio, C; Ascoli, V; Dianzani, C; Colombo, E; Piccolini, E; Pavesi, M; Miccoli, S; Mirabelli, D; Bracco, C; Righi, L; Boldorini, R; Papotti, M; Matullo, G; Magnani, C; Pasini, B; Dianzani, I
Changes in prostatic cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience 2008 Bollito E; Terrone C; Volpe A; Porpiglia F; Cracco C; Poggio M; Grande S; Righi L; Bellina M; Papotti M; Scarpa RM
Classification of pulmonary neuroendocrine tumors: New insights 2017 Pelosi, Giuseppe; Sonzogni, Angelica; Harari, Sergio; Albini, Adriana; Bresaola, Enrica; Marchiò, Caterina; Massa, Federica; Righi, Luisella; Gatti, Gaia; Papanikolaou, Nikolaos; Vijayvergia, Namrata; Calabrese, Fiorella; Papotti, Mauro
Clinical and biological significance of CD157 in malignant pleural mesothelioma 2011 S. Morone; E. Ortolan; A. Giacomino; R. Parrotta; N. Lo Buono; I. Rapa; L. Righi; M. Volante; E. Ruffini; S. Demichelis; G. Rovere; S. Novello; F. Malavasi; A. Funaro.
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 2021 Bironzo P.; Reale M.L.; Sperone T.; Tabbo F.; Caglio A.; Listi A.; Passiglia F.; Di Maio M.; Righi L.; Bussolino F.; Scagliotti G.V.; Novello S.
Clinical significance of neuroendocrine carcinoma of the breast. 2001 SAPINO A; PAPOTTI M; RIGHI L; CASSONI P; CHIUSA L; G. BUSSOLATI
Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response 2022 Bironzo, Paolo; Primo, Luca; Novello, Silvia; Righi, Luisella; Candeloro, Silvana; Manganaro, Lorenzo; Bussolino, Federico; Pirri, Fabrizio; Scagliotti, Giorgio V
Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma 2014 Eleonora Duregon;Luca Molinaro;Marco Volante;Laura Ventura;Luisella Righi;Stefania Bolla;Massimo Terzolo;Anna Sapino;Mauro G Papotti